Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer

The five-year survival rate for metastatic pancreatic cancer is currently only 3%, which increases to 13% with local invasion only and to 39% with localized disease at diagnosis. Here we evaluated repurposed mebendazole, an approved anthelminthic drug, to determine how mebendazole might work at the...

Descripción completa

Detalles Bibliográficos
Autores principales: Williamson, Tara, de Abreu, Michelle Carvalho, Trembath, Dimitri G., Brayton, Cory, Kang, Byunghak, Mendes, Thais Biude, de Assumpção, Paulo Pimentel, Cerutti, Janete M., Riggins, Gregory J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274724/
https://www.ncbi.nlm.nih.gov/pubmed/34262644
http://dx.doi.org/10.18632/oncotarget.28014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274724/
https://www.ncbi.nlm.nih.gov/pubmed/34262644
http://dx.doi.org/10.18632/oncotarget.28014

Ejemplares similares